{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:19Z","timestamp":1790916979247,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11523-026-01241-0","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:40:38Z","timestamp":1788144038000},"page":"643-651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of Recurrence in Patients with HR+\/HER2\u2212 Early Breast Cancer: A Podcast"],"prefix":"10.1007","volume":"21","author":[{"given":"Maryam B.","family":"Lustberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan-Claire","family":"Chase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Tinianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kalinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"19","key":"1241_CR1","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1701830.","journal-title":"N Engl J Med"},{"key":"1241_CR2","doi-asserted-by":"publisher","unstructured":"EBCTCG. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155\u2008746 women in 151 trials. Lancet. 2024;404(10461):1407\u201318. https:\/\/doi.org\/10.1016\/s0140-6736(24)01745-8.","DOI":"10.1016\/s0140-6736(24)01745-8"},{"key":"1241_CR3","doi-asserted-by":"publisher","unstructured":"Curigliano G, Ciruelos E, Kalinsky K, et al. Short-term risk of recurrence in patients with HR+\/ HER2\u2212 early breast cancer treated with endocrine therapy in randomized clinical trials: a meta-analysis. J Clin Oncol. 2024;42(16_Suppl.):541. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.541.","DOI":"10.1200\/JCO.2024.42.16_suppl.541"},{"issue":"16_Suppl.","key":"1241_CR4","doi-asserted-by":"publisher","first-page":"e12533","DOI":"10.1200\/JCO.2024.42.16_suppl.e12533","volume":"42","author":"P Razavi","year":"2024","unstructured":"Razavi P, Ahmed M, Roush A, et al. Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+\/HER2- early breast cancer (EBC) treated with endocrine therapy (ET) in the US. J Clin Oncol. 2024;42(16_Suppl.):e12533. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e12533.","journal-title":"J Clin Oncol"},{"issue":"16","key":"1241_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1200\/jco.18.01933","volume":"37","author":"J Foldi","year":"2019","unstructured":"Foldi J, O\u2019Meara T, Marczyk M, Sanft T, Silber A, Pusztai L. Defining risk of late recurrence in early-stage estrogen receptor-positive breast cancer: clinical versus molecular tools. J Clin Oncol. 2019;37(16):1365\u20139. https:\/\/doi.org\/10.1200\/jco.18.01933.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1241_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.molonc.2016.09.009","volume":"11","author":"RR Gomis","year":"2017","unstructured":"Gomis RR, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2017;11(1):62\u201378. https:\/\/doi.org\/10.1016\/j.molonc.2016.09.009.","journal-title":"Mol Oncol"},{"issue":"16_Suppl.","key":"1241_CR7","doi-asserted-by":"publisher","first-page":"e23303","DOI":"10.1200\/JCO.2024.42.16_suppl.e23303","volume":"42","author":"M Marques","year":"2024","unstructured":"Marques M, Gambaro K, Basik M, et al. Evaluation of recurrence rate in Canadian patients with stage II\/III HR+\/HER2- early breast cancer in the real-world setting. J Clin Oncol. 2024;42(16_Suppl.):e23303. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e23303.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1241_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/jnci\/djae241","volume":"117","author":"M Marczyk","year":"2025","unstructured":"Marczyk M, Kahn A, Silber A, et al. Trends in breast cancer-specific death by clinical stage at diagnoses between 2000 and 2017. J Natl Cancer Inst. 2025;117(2):287\u201395. https:\/\/doi.org\/10.1093\/jnci\/djae241.","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"1241_CR9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1158\/1078-0432.Ccr-23-4020","volume":"30","author":"M Bottosso","year":"2024","unstructured":"Bottosso M, Miglietta F, Vernaci GM, et al. Gene expression assays to tailor adjuvant endocrine therapy for HR+\/HER2- breast cancer. Clin Cancer Res. 2024;30(14):2884\u201394. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-4020.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1241_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105521","volume":"10","author":"C Corti","year":"2025","unstructured":"Corti C, Chu X, Exman P, et al. Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive\/HER2-negative breast cancer: a single-center prospective observational study. ESMO Open. 2025;10(8):105521. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105521.","journal-title":"ESMO Open"},{"issue":"9","key":"1241_CR11","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1158\/1078-0432.Ccr-21-3385","volume":"28","author":"JMS Bartlett","year":"2022","unstructured":"Bartlett JMS, Sgroi DC, Treuner K, et al. Breast Cancer Index is a predictive biomarker of treatment benefit and outcome from extended tamoxifen therapy: final analysis of the Trans-aTTom study. Clin Cancer Res. 2022;28(9):1871\u201380. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-3385.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1241_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/1078-0432.Ccr-20-2737","volume":"27","author":"I Noordhoek","year":"2021","unstructured":"Noordhoek I, Treuner K, Putter H, et al. Breast cancer index predicts extended endocrine benefit to individualize selection of patients with HR(+) early-stage breast cancer for 10 years of endocrine therapy. Clin Cancer Res. 2021;27(1):311\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2737.","journal-title":"Clin Cancer Res"},{"key":"1241_CR13","doi-asserted-by":"publisher","unstructured":"Janni W, Untch M, Harbeck N, et al. Comparing the efficacy of aromatase inhibitors vs tamoxifen in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and trial-level meta-analysis. Cancer Res. 2022;83(5_Suppl.):P1-02-01. https:\/\/doi.org\/10.1158\/1538-7445.SABCS22-P1-02-01.","DOI":"10.1158\/1538-7445.SABCS22-P1-02-01"},{"key":"1241_CR14","doi-asserted-by":"publisher","unstructured":"Harbeck N, Gluz O, Christgen M, et al. Ribociclib + endocrine treatment vs SoC chemotherapy in intermediate risk HR+\/HER2\u2212 early breast cancer: results from the neoadjuvant cohort of the phase-III WSG ADAPTcycle trial. ESMO Open. 2025;10(4_Suppl.):104743. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104743","DOI":"10.1016\/j.esmoop.2025.104743"},{"issue":"21","key":"1241_CR15","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1200\/jco.2015.63.8619","volume":"34","author":"JH Chirgwin","year":"2016","unstructured":"Chirgwin JH, Giobbie-Hurder A, Coates AS, et al. Treatment adherence and its impact on disease-free survival in the Breast International Group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol. 2016;34(21):2452\u20139. https:\/\/doi.org\/10.1200\/jco.2015.63.8619.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1241_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10549-018-4890-z","volume":"172","author":"W Wulaningsih","year":"2018","unstructured":"Wulaningsih W, Garmo H, Ahlgren J, et al. Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity. Breast Cancer Res Treat. 2018;172(1):167\u201377. https:\/\/doi.org\/10.1007\/s10549-018-4890-z.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"1241_CR17","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","volume":"390","author":"D Slamon","year":"2024","unstructured":"Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390(12):1080\u201391. https:\/\/doi.org\/10.1056\/NEJMoa2305488.","journal-title":"N Engl J Med"},{"issue":"1","key":"1241_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/s1470-2045(22)00694-5","volume":"24","author":"SRD Johnston","year":"2023","unstructured":"Johnston SRD, Toi M, O\u2019Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(1):77\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(22)00694-5.","journal-title":"Lancet Oncol"},{"issue":"18","key":"1241_CR19","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","volume":"375","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1609709.","journal-title":"N Engl J Med"},{"issue":"24","key":"1241_CR20","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465\u201372. https:\/\/doi.org\/10.1200\/JCO.2018.78.9909.","journal-title":"J Clin Oncol"},{"key":"1241_CR21","doi-asserted-by":"publisher","unstructured":"Tripathy D, Campos-Gomez S, Lu Y-S, et al. Ribociclib with a nonsteroidal aromatase inhibitor and goserelin in premenopausal women with HR-positive, HER2\u2212negative ABC: MONALEESA-7 age subgroup analysis. Cancer Res. 2019;79(4_Suppl.):P6-18-04. https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-P6-18-04.","DOI":"10.1158\/1538-7445.SABCS18-P6-18-04"},{"issue":"1","key":"1241_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0661-5","volume":"18","author":"RS Finn","year":"2016","unstructured":"Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers. Breast Cancer Res. 2016;18(1):17. https:\/\/doi.org\/10.1186\/s13058-015-0661-5.","journal-title":"Breast Cancer Res"},{"issue":"3","key":"1241_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1505270.","journal-title":"N Engl J Med"},{"issue":"25","key":"1241_CR24","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.73.7585.","journal-title":"J Clin Oncol"},{"issue":"32","key":"1241_CR25","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.75.6155.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1241_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s12276-020-0423-z","volume":"52","author":"SY Park","year":"2020","unstructured":"Park SY, Nam JS. The force awakens: metastatic dormant cancer cells. Exp Mol Med. 2020;52(4):569\u201381. https:\/\/doi.org\/10.1038\/s12276-020-0423-z.","journal-title":"Exp Mol Med"},{"issue":"34","key":"1241_CR27","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/jco.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398. https:\/\/doi.org\/10.1200\/jco.20.02514.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1241_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105858","volume":"10","author":"J Crown","year":"2025","unstructured":"Crown J, Stroyakovskii D, Yardley DA, et al. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive\/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025;10(11):105858. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105858.","journal-title":"ESMO Open"},{"issue":"2","key":"1241_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","volume":"37","author":"S Johnston","year":"2026","unstructured":"Johnston S, Martin M, O\u2019Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37(2):155\u201365. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.005.","journal-title":"Ann Oncol"},{"issue":"13","key":"1241_CR30","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1158\/1078-0432.Ccr-16-3157","volume":"23","author":"D Tripathy","year":"2017","unstructured":"Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): mechanism of action and clinical impact of this selective cyclin-dependent kinase 4\/6 inhibitor in various solid tumors. Clin Cancer Res. 2017;23(13):3251\u201362. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-3157.","journal-title":"Clin Cancer Res"},{"key":"1241_CR31","doi-asserted-by":"publisher","first-page":"175883592311528","DOI":"10.1177\/17588359231152843","volume":"15","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Harmer V, O\u2019Shaughnessy J, et al. Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+\/HER2\u2212 advanced breast cancer: a matching-adjusted indirect comparison. Ther Adv Med Oncol. 2023;15:17588359231152844. https:\/\/doi.org\/10.1177\/17588359231152843.","journal-title":"Ther Adv Med Oncol."},{"key":"1241_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103101","author":"CH Barrios","year":"2024","unstructured":"Barrios CH, Harbeck N, Hortobagyi GN, et al. 113MO NATALEE update: safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+\/HER2- early breast cancer (EBC). ESMO Open. 2024. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103101.","journal-title":"ESMO Open"},{"issue":"25","key":"1241_CR33","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2105215.","journal-title":"N Engl J Med"},{"issue":"9","key":"1241_CR34","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/1078-0432.Ccr-24-1724","volume":"31","author":"PA Fasching","year":"2025","unstructured":"Fasching PA, Slamon D, Nowecki Z, et al. Health-related quality of life in patients with HR+\/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial. Clin Cancer Res. 2025;31(9):1625\u201335. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1724.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1241_CR35","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/jco.23.01214","volume":"42","author":"PA Ganz","year":"2024","unstructured":"Ganz PA, Bandos H, \u0160pani\u0107 T, et al. Patient-reported outcomes in OlympiA: a phase III, randomized, placebo-controlled trial of adjuvant olaparib in gBRCA1\/2 mutations and high-risk human epidermal growth factor receptor 2-negative early breast cancer. J Clin Oncol. 2024;42(11):1288\u2013300. https:\/\/doi.org\/10.1200\/jco.23.01214.","journal-title":"J Clin Oncol"},{"key":"1241_CR36","unstructured":"National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http:\/\/Ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 20 July 2026."},{"key":"1241_CR37","doi-asserted-by":"publisher","unstructured":"Garber J, Cameron D, Campbell C, et al. OlympiA: phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/germline BRCA1\/BRCA2 pathogenic variants & high risk HER2\u2212 negative primary breast cancer; longer term follow-up. Clin Cancer Res. 2025;31(12_Suppl.):GS1-09. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-GS1-09.","DOI":"10.1158\/1557-3265.SABCS24-GS1-09"},{"key":"1241_CR38","unstructured":"Kisqali\u00ae (ribociclib) [package insert]. East Hanover: Novartis Pharmaceuticals Corporation; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209092s024lbl.pdf. Accessed 30 Apr 2026."},{"key":"1241_CR39","unstructured":"Verzenio\u00ae [prescribing information]. Indianapolis: Eli Lilly and Company; 2025. April 30, 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208716s000lbl.pdf. Accessed 20 July 2026."},{"key":"1241_CR40","unstructured":"Lynparza\u00ae [prescribing information]. Wilmington: AstraZeneca Pharmaceuticals LP; 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/208558s031lbl.pdf. Accessed 20 July 2026."}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01241-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01241-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01241-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:59Z","timestamp":1790916719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01241-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01241-0","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Maryam B. Lustberg reports honoraria from Novartis and a consulting or advisory role for AstraZeneca, Gilead Sciences, Lilly, and Pfizer. Kevin Kalinsky reports employment stock of his spouse from EQRX, Grail (prior employee); personal fees for advisory\/consulting from Eli Lilly, Pfizer, Novartis, AstraZeneca, Daiichi Sankyo, Puma, 4D Pharma, OncoSec, Immunomedics, Merck, Seattle Genetics, Mersana, and Cyclocel; and institutional research funding from Genentech\/Roche, Novartis, Lilly, AstraZeneca, Daiichi Sankyo, and Ascentages. Megan-Claire Chase and Stacey Tinianov have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed to the conceptualization, writing, reviewing, and editing of this work.","order":7,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}